



HAL
open science

Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors

Rebecca Xicluna, Allan Avenel, Céline Vandamme, Marie Devaux, Nicolas Jaulin, Célia Couzinié, Johanne Le Duff, Alicia Charrier, Mickaël Guilbaud, Oumeya Adjali, et al.

► **To cite this version:**

Rebecca Xicluna, Allan Avenel, Céline Vandamme, Marie Devaux, Nicolas Jaulin, et al.. Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and rh10 in Healthy Donors. *Human Gene Therapy*, 2024, 35 (9-10), pp.355-364. 10.1089/hum.2023.225 . hal-04809731

HAL Id: hal-04809731

<https://nantes-universite.hal.science/hal-04809731v1>

Submitted on 6 Jan 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Prevalence study of cellular capsid-specific immune responses to AAV1, 2, 4, 5, 8, 9 and rh10 reveals particular features for AAV9

Authors: Rebecca XICLUNA^{1,#,†}, Allan AVENEL^{1,#}, Céline VANDAMME^{1,‡}, Marie DEVAUX¹, Nicolas JAULIN¹, Célia COUZINIE¹, Johanne LE DUFF¹, Alicia CHARRIER¹, Mickaël GUILBAUD¹, Oumeya ADJALI^{1,*} and Gwladys GERNOUX^{1,*}.

Affiliations: (1) Nantes Université, CHU de Nantes, INSERM, TaRGeT - Translational Research in Gene Therapy, UMR 1089, F-44200 Nantes, France.

co-first authors.

† Current affiliation: I2S, Roche pRED Pharmaceutical Sciences, Basel, Switzerland.

‡ Current affiliation: Charles River Laboratories, Evreux, France.

*co-corresponding authors

This work was performed at INSERM TaRGeT UM1089, Nantes, France.

* **Correspondence should be addressed to** Gwladys Gernoux (gwladys.gernoux@univ-nantes.fr), 22 Bd Benoni Goullin, 44200 Nantes, France; +33 2 28 08 04 60 and Oumeya Adjali (oumeya.adjali@univ-nantes.fr); 22 Bd Benoni Goullin, 44200 Nantes, France; +33 2 28 08 04 22.

Short Title: Cellular prevalence to AAV2, 4, 5, 8, 9 and rh10

Keywords: AAV, gene therapy, prevalence, cellular immune response, anti-AAV T cells and anti-AAV IgG

ABSTRACT:

Recombinant adeno-associated virus (rAAV) vectors appear, more than ever, to be efficient viral vectors for *in vivo* gene transfer as illustrated by the approvals of 7 drugs across Europe and the USA. Nevertheless, pre-existing immunity to AAV capsid in humans remains one of the major limits for a successful clinical translation. Whereas pre-existing humoral response to AAV capsid is well documented, the prevalence of pre-existing capsid-specific T cell responses still needs to be studied and characterized. Here, we investigated the prevalence of AAV-specific circulating T cells towards AAV2, 4, 5, 8, 9 and rh10 in a large cohort of healthy donors using the standard IFN γ ELISpot assay. We observed the highest prevalence of pre-existing cellular immunity to AAV9 serotype followed by AAV8, AAV4, AAV2, AAVrh10 and AAV5 independently of the donor's serological status. An in-depth analysis of T cell responses towards the 2 most prevalent serotypes 8 and 9 shows that IFN γ secretion is mainly mediated by CD8 T cells for both serotypes. A polyfunctional analysis reveals different cytokine profiles between AAV8 and AAV9. Surprisingly, no IL-2 secretion was mediated by anti-AAV9 immune cells suggesting that these cells are rather exhausted than cytotoxic T cells. Altogether, these results suggest that pre-existing immunity to AAV may vary depending on the serotype and support the necessity of using multiparametric monitoring methods to better characterize anti-capsid cellular immunity and foresee its impact in rAAV-mediated clinical trials.

INTRODUCTION:

Recombinant adeno-associated viral vectors (rAAV)-mediated gene therapy shows promising benefits for the treatment of genetic disorders as illustrated by Glybera®, Luxturna®, Zolgensma®, Upstaza®, Roctavian®, Hemgenix® and Elevidys® FDA and EMA approvals and more than 230 clinical trials ongoing ((1) and clinicaltrials.gov). However, there are still major hurdles to overcome for their successful clinical translation such as their immunogenicity in patients. Indeed, since protocols evolved from local to systemic delivery with high doses of vector, adverse events related to the immune system activation have been reported in treated patients, resulting in some cases in regulatory holds of clinical trials (2).

Seroprevalence studies showed that human population is exposed to wild-type (WT) AAV virus early in life (3) and might present a memory immune response that can be reactivated after gene transfer. These studies were mainly conducted on human serum samples to evidence the presence of anti-AAV neutralizing antibodies (4,5) that will prevent target cell transduction after vector administration but little is known about the anti-AAV memory T cell response prevalence in humans. Importantly, these pre-existing anti-AAV memory T cells might be reactivated after gene transfer and lead to gene transfer failure as previously described in a clinical trial targeting Hemophilia B patients (6,7). In this trial, the intrahepatic injection of rAAV2 led to the destruction of liver transduced cells 4-8 weeks after vector delivery due to the reactivation of pre-existing IFN γ -secreting AAV-specific CD8 T cells. Since then, the liver transaminase elevation due to hepatotoxicity and the IFN γ secretion in response to AAV capsid are systematically measured in clinical trials and managed by corticosteroid treatment (8–10).

To our knowledge, in the general population, only cellular responses directed to AAV2, AAV1, AAV5 and AAV8 (11–13) have been investigated so far, which does not cover the whole diversity of rAAV serotypes now used in clinical trials. Indeed, no cellular prevalence data in

humans are reported for the AAV9 capsid which is used in a commercialized product since 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients (14). AAV9 serotype is also used in clinical trials targeting Pompe (NCT02240407), Canavan (NCT04998396), GM1 gangliosidosis (NCT03952637) and Parkinson (NCT04127578) diseases as well as Duchenne Muscular Dystrophy (NCT04240314, NCT03368742 and NCT03362502). The AAVrh10 has also emerged lately as a good candidate for gene delivery to the central nervous system and showed promising results for clinical applications targeting Krabbe disease (15), metachromatic leukodystrophy (16 and NCT01801709), GM1 gangliosidosis (17 and NCT04273269) or ALS (8,18).

Here, we investigated the prevalence of AAV-specific circulating T cells towards AAV2, 4, 5, 8, 9 and rh10 in a large cohort of healthy donors using an IFN γ ELISpot assay that is usually used in immune monitoring in clinical studies. We observed the highest prevalence of pre-existing cellular immunity against AAV9 serotype followed by AAV8, AAV4, AAV2, AAVrh10 and AAV5. As already described, there was no correlation in our cohort between the cellular immune response and the humoral anti-capsid immunity. An in-depth analysis of T cell responses towards the 2 most prevalent serotypes 8 and 9 shows that IFN γ secretion is mainly mediated by CD8 T cells for both serotypes. We also performed FluoroSpot assays that showed their potential as a polyfunctional assay to characterize anti-AAV T cell responses to be used in clinical trials as we observed different cytokine profiles between AAV8 and AAV9. This observation suggests a different functional impact of preexisting capsid-specific T cells in rAAV-mediated clinical trials.

Our data suggest that pre-existing anti-AAV cellular immune responses are serotype-dependent and encourage the use of multiparametric monitoring methods to better characterize capsid-specific cellular immune responses and predict their impact in rAAV-mediated clinical trials.

MATERIALS AND METHODS:

All this work was performed at INSERM TaRGeT UM1089, Nantes, France under the control of our quality management system that is approved by Lloyd's Register Quality Assurance LRQA to meet requirements of international Management System Standards ISO 9001:2015. It has been implemented to cover all activities in the laboratory, including research experiments and production of research-grade viral vectors.

Healthy donor blood samples

Cytapheresis samples were provided by the local Etablissement Français du Sang (EFS Nantes, Pays de la Loire, agreements N° PLER NTS 2016-25 and CPDL-PLER-2021 005) and originated from consenting healthy donors living in the Pays de la Loire area, France (22 women and 129 men with age ranging from 19 to 72 years old). All the participants gave their written informed consent. PBMCs were isolated using Ficoll density gradient centrifugation (Ficoll-Paque PLUS, GE Healthcare) and frozen in liquid nitrogen for ELISpot and Fluoropost assays. Plasma were isolated by spinning 10min at 2000rpm, RT 10ml of whole blood and were stored at -20°C.

IFN γ ELISpot assay on healthy donor PBMCs

Anti-AAV cellular immune responses were analyzed using an IFN γ ELISpot assay. ELISpot assays were performed according to the manufacturer's recommendations (ELISpot Plus: Human IFN- γ (ALP) kit, MABTech). Briefly, PBMCs from healthy donors were stimulated *in vitro* for 18-48h with overlapping peptides spanning the VP1 capsid protein sequence (which also covers VP2 and VP3) of each serotype (*i.e.* AAV2, 4, 5, 8, 9 and rh10) and divided into 3 pools (15-mers overlapping by 10 aa, Sigma-Aldrich, United States or Mimotopes, Australia). A negative control consisted of unstimulated cells (medium only), whereas concanavalin A (Con A, 10 μ g/mL, Sigma-Aldrich, United States) stimulation was used as a positive control

for cytokine secretion. Spot number was determined using an ELISpot iSpot Spectrum reader (AID, Strassberg, Germany) and a Mabtech IRIS reader and analyzed with AID ELISpot reader Software V7.0 (AID, Strassberg, Germany) and Mabtech APEX v1.1 software (Mabtech, Sweden) respectively. Responses were considered positive when the number of spot-forming colonies (SFCs) *per* 1e6 cells were >50 and at least 3-fold higher than the negative control condition.

Anti-AAV IgG ELISA

Detection of anti-AAV total IgG antibodies for each serotype in the plasma of healthy human donors was conducted using an enzyme-linked immunosorbent assay (ELISA). Nunc Maxisorp P96 plates (Sigma-Aldrich) were coated overnight at 4°C with rAAV2, rAAV8, rAAV9 or rAAVrh10 particles (INSERM UMR 1089 Vector Core Facility). After washing and plate saturation, wells were then incubated for 1 hour at 37°C with at least 6 serial 4-fold dilutions of human plasma starting at 1:10 followed by HRP-conjugated anti-human F(ab')₂ IgG antibody (Jackson) for 1 hour at 37°C. Revelation was performed using 3,3',5,5'-Tetramethylbenzidine (TMB, OptEIA, BD Biosciences) and absorbance of duplicate samples was read at 450 nm with a correction at 570 nm on a MultiSkan Go reader (Thermo Scientific). Positive threshold curves for each ELISA were determined from seronegative human sera (> 20 donors) as the mean optic density (O.D.) for each dilution + 2xSD. For each donor, anti-AAV IgG titer was defined as the last plasma dilution with an O.D. remaining above the threshold curve.

IFN γ ELISpot assay on healthy donor CD4- or CD8-depleted PBMCs

CD4⁺ or CD8⁺ T cells were depleted from total PBMCs using Stem Cell magnetic-based system (EasySepTM Human CD4/CD8 Positive Selection Kit II) according to manufacturer's recommendations. Cell depletion efficiency was determined by flow cytometry before (total PBMCs) and after magnetic separation (CD4- and CD8-depleted PBMCs). Briefly, CD4⁺ T

cell and CD8⁺ T cell populations were analyzed using CD3 (557749; BD Biosciences), CD19 (561031; BD Biosciences), CD4 (560251; BD Biosciences) and CD8 (93-0088-42; eBiosciences) markers. CD4 and CD8 T cells were gated as CD4⁺ or CD8⁺ cells respectively within the CD3⁺CD19⁻ population. Cells were acquired using a BD FACS LSRII flow cytometer (BD Biosciences) and analyzed with FlowJo™ software (v.10; BD Life Sciences). Anti-AAV cellular responses were assessed using the IFN γ ELISpot assay described above.

IFN γ /IL-2/TNF α Fluorospot assay on healthy donor PBMCs

Anti-AAV cellular immune responses were also evaluated using IFN γ /IL-2/TNF α FluoroSpot assays. FluoroSpot assays were performed according to the manufacturer's recommendations (FluoroSpot Plus: Human IFN γ /IL-2/TNF α kit, MABTech). Briefly, PBMCs from healthy donors were stimulated *in vitro* for 48h with the same AAV8 and AAV9 peptide libraries used for IFN γ -ELISpot assays described above. A negative control consisted of unstimulated cells (medium only), whereas concanavalin A (Con A, 10 μ g/mL, Sigma-Aldrich, United States) stimulation was used as a positive control for cytokine secretion. Spot number was determined using an ELISpot iSpot Spectrum reader (AID, Strassberg, Germany) and analyzed with AID ELISpot reader Software V7.0 (AID, Germany). Responses were considered positive when the number of spot-forming colonies per million cells was > 50 and at least threefold higher than the medium alone negative control.

RESULTS:

Cellular immune response prevalence to AAV2, 4, 5, 8, 9 and rh10 in healthy donors.

The prevalence of preexisting cellular immune response to AAV serotypes 2, 4, 5, 8, 9 and rh10 was determined using an IFN γ ELISpot assay. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood collected on healthy human donors (n=45-145 depending on serotypes) from the Pays de la Loire area, France. These cells were restimulated *in vitro* with an overlapping peptide library spanning the VP1 sequence of each serotypes tested (*i.e.* AAV2, 4, 5, 8, 9 and rh10) and divided into 3 pools. Our results show that AAV9 and AAV8 have the highest prevalence: 46% (n=66/145) and 24% (n=35/145) of positive donors respectively followed by AAV4 (10%, n=8/80), AAVrh10 (9%, n=4/45), and AAV2 (7%, n=9/121). Only 1 donor out of 84 was found positive for an IFN γ -positive response to AAV5 (**Figure 1A**). As expected, due to their strong homology, a coprevalence analysis reveals that 26% of positive donors are also reacting to 2 or more serotypes (**Figure 1B** and **Table 1**). It is noteworthy that all the positive donors to AAV2 are also responding to at least another serotype in contrast to AAV4, AAV8, AAV9 and AAVrh10. All of the AAV2-positive donors are positive for an anti-AAV8 cellular response. The only AAV5-positive donor shows a response to AAV8, AAV9 and AAVrh10 as well. This donor has a positive response towards the AAV pool 2 of AAV5, 8, 9 and rh10 suggesting a shared epitope (**Supplementary Table S1**). Regarding the AAV8, 31% of the positive donors are also responding to AAV2 and 54% are also positive to AAV9. Interestingly, 73% of AAV9-positive donors are reactive to this serotype only and 27% were found positive for at least another serotype.

Cellular and humoral immune responses to AAV2, 8, 9 and rh10 are not correlated.

We focused on AAV2 and AAV8 since these serotypes have been studied previously and on AAV9 and rh10 serotypes as they are frequently used in preclinical studies and clinical trials

currently and for which there is less data available in the literature. For these 4 serotypes, we investigated the humoral response prevalence by analyzing the presence of anti-AAV total immunoglobulins G (IgGs) by ELISA in the serum of healthy donors (**Figure 2A**). As already reported, we observed a high seroprevalence to AAV2 (40%, n=96) and AAV8 (43%, n=109) (5,11). AAV9 and AAVrh10 show a lower seroprevalence: 29% (n=109) and 26% (n=39) respectively. We analyzed the coprevalence of AAV-specific IgG in 38 healthy donors (**Table 2**). Eight donors (21%) were positive for the 4 serotypes. Our results show that 85% of the donors positive for anti-AAV2 IgGs are positive for AAV8 and 77% for AAV9 and AAVrh10 capsids. However, in donors positive for anti-AAV8 and anti-AAV9 IgGs, 71 to 79% are positive to AAV2 capsid. 93% of the donors with anti-AAV8 IgGs are responsive to AAV9 and reciprocally. Interestingly, all donors with anti-AAVrh10 antibodies are responding to AAV2 and AAV8 and 90% are responsive to AAV9.

Finally, we analyzed the correlation between the T cell responses and the antibody responses to AAV in our cohort (**Figure 2B**). For AAV2, we observed that 85% of the IgG-positive donors (n=39/96) do not show an IFN γ secretion to the capsid. For AAV8, we observed that 68% of the IgG-positive donors (n=47/109) do not show an IFN γ secretion to the capsid. For AAV9, we observed that 42% of the IgG-positive donors (n=26/88) do not show an IFN γ secretion to the capsid. Surprisingly, none of donors that are positive for anti-AAVrh10 IgG-positive donors (n=10/39) show an IFN γ secretion to the capsid; the donors with a cellular immune response represent 10% of the donors who do not have anti-AAVrh10 IgGs. Our results confirmed, as previously reported by others, that there is no correlation between the T cell responses and the antibody responses to AAV in our cohort.

IFN γ -secretion to AAV8 and AAV9 is predominantly mediated by CD8 T cells.

Since AAV8 and AAV9 show the highest cellular prevalence (24% and 46% respectively) and are serotypes currently preferred for high systemic dosing in patients, we wanted to further

characterize the cellular immune response. We wondered whether CD8 or CD4 T cells were mediating IFN γ secretion. We performed additional IFN γ ELISpot assays in a representative cohort of positive donors (n=8 per serotype) using total PBMCs, CD4- or CD8-depleted PBMCs. The efficiency of each CD4 and CD8 depletion was evaluated by flow cytometry and shows less than 1% of remaining targeted cells after depletion (**Figure 3A** shows one representative donor). These depletions showed that in all positive donors to AAV8 (n=8), IFN γ secretion was mediated by CD8 T cells (i.e. by CD4-depleted PBMCs, **Figure 3B** for one representative donor). No IFN γ secretion was observed in the CD8-depleted fraction for all donors tested (**Supplementary Table S2**). Regarding the AAV9 serotype, 8 positive donors were analyzed and also showed that IFN γ secretion was mediated by CD8 T cells (i.e. by CD4-depleted PBMCs, **Figure 3B**). Nevertheless, in 4 out of 8 donors, we also observed a significant IFN γ secretion by CD4 T cells (i.e. by CD8-depleted PBMCs) despite an efficient CD8 depletion (**Figure 3C** for one representative donor and **Supplementary Table S2**). Therefore, IFN γ secretion seems to be mainly mediated by CD8 T cells in response to AAV9 with some donors also showing an IFN γ secretion mediated by CD4 T cells.

Cytokine secretion profile of preexisting anti-AAV T cells differ between AAV8 and AAV9.

We further characterized the preexisting cellular immune response to AAV8 and AAV9 by performing a polyfunctional FluoroSpot assay. We evaluated the secretion of 3 cytokines indicative of a cytotoxic phenotype simultaneously: IFN γ , IL-2 and TNF α (**Figure 4A**). The PBMCs were restimulated *in vitro* with overlapping peptide libraries spanning the AAV8 or AAV9 VP1 sequence. Six and 8 donors showing an IFN γ -positive response to AAV8 and AAV9 respectively were tested (**Figure 4B**). For each donor, we determined within the IFN γ -secreting cell population whether the cells had 1 (IFN γ ⁺ only), 2 (IFN γ ⁺ only and IFN γ +IL-2⁺ or IFN γ ⁺ only and IFN γ +TNF α ⁺) or 4 functions: (IFN γ ⁺ only, IFN γ +IL-2⁺, IFN γ +TNF α ⁺

and IFN γ +IL-2+TNF α +). For the AAV8, we observed a diversity in the immune response profile among the 6 donors: 3/6 donors have cells showing 1, 2 and 4 functions, 2/6 donors have cells with 2 functions (IFN γ + only and IFN γ +TNF α +) and 1/6 donor has cells with 1 function (IFN γ + only). Surprisingly, for the AAV9, all the donors (n=8) show the same pattern: 2 functions (IFN γ + only and IFN γ +TNF α); no IL-2 secretion was detected in any tested donors. Despite a limited number of healthy donors, our results suggest that preexisting cellular immune responses might differ between AAV8 and AAV9.

DISCUSSION

Recombinant AAVs are successful viral vectors for the treatment of inherited disorders as illustrated by recent EMA and FDA approvals of these vectors for the treatment of Leber congenital amaurosis (LCA) (19), spinal muscular atrophy (SMA) (20), hemophilia A (21) and B (22), aromatic L-amino acid decarboxylase deficiency (AADC) (23) and DMD (24) and more than 230 clinical trials ongoing. However, when protocols were translated from preclinical models to patients, some limits related to the host immune response emerged and remain a major hurdle since protocols evolved from local to systemic injection of high doses of AAV vectors.

Pre-existing immunity to AAV capsid is one of the major limits for successful clinical translation of rAAV gene therapy products. To our knowledge, only the prevalence of pre-existing cellular immunity to AAV1, AAV2, AAV5 and AAV8 has been assessed in the general populations so far (11–13,25). Cellular immunity towards more recently emerging serotypes such as AAV9 or AAVrh10 have not been reported yet whereas they are used in 33 and 10 active or recruiting clinical trials respectively (clinicaltrials.gov database). Here, we studied the prevalence of the cellular immune response to 6 AAV serotypes: AAV2, 4, 5, 8, 9 and rh10 in a large cohort of healthy donors. Our results show that AAV9 is most prevalent (46%) followed

by AAV8 (24%), AAV4 (10%), AAVrh10 (9%), AAV2 (7%) and AAV5 (1%). The AAV2 prevalence is comparable to results obtained by Chirmule et al. (25) in a cohort of 45 healthy donors from USA but lower than reported by Li *et al.* (47%, n=17) (13) or by Kruzik *et al.* (19%, n=90) (11). In this study, they also described a prevalence of 24% for the AAV5 whereas we showed only 1 positive donor out of 84. These differences across studies might be explained by the different assays used and the absence of standardization of these assays (e.g. discrepancy for the positive thresholds determined in different ELISpot assays) but also by an analysis performed on donors coming from different countries or continents (France *versus* Germany, Austria and USA) which has an impact on natural AAV infections as previously shown for humoral prevalence (4). These differences highlight the need of standardized assays to compare studies and to measure T-cell mediated immune response to AAV prior and post gene therapy in clinic.

The humoral immune response to AAV2,8, 9 and rh10 has also been analyzed. As already described, the highest IgG prevalence is observed for AAV2 (4,5) and AAV8 followed by AAV9 and rh10. This is in accordance with previous studies performed on anti-AAV neutralizing antibodies (NAbs) and/or total IgG antibodies (TAbS) (4,5,11,26). As for the monitoring of anti-AAV cellular immune responses, some variability may apply between studies since there is no standardized assay with a defined cut-off to measure either NAbs or TAbS in healthy donors or patients enrolled in clinical trials (1:10 in the present study *versus* 1:20 (11) or 1:30 (5) for example). Moreover, the seroprevalence may vary depending on the age of the donors and their origin (3,4,11). As previously described, our results confirm there is a high cross reactivity between serotypes; more than 88% of donors responding to AAV2 are responding to AAV8 and 93% of the donors responding to AAV8 are responding to AAV9. The more cross-reactive donors are the ones positive for anti-AAVrh10 (n=9/39). This can be

explained by phylogenetic relatedness (27,28). Our study also confirms there is no correlation between humoral and the IFN γ -mediated cellular immune responses to AAV vectors (11,12).

As expected, we also report a cellular immune response cross-reactivity between serotypes. This analysis was performed on 73 donors for serotypes 2, 4, 5, 8 and 9 and on 40 donors for serotypes 2, 8, 9 and rh10. Our results show that 26% of the positive donors are also reacting to 2 or more serotypes. All the positive donors to AAV2 were also found responsive to at least another serotype in contrast to AAV4, AAV8, AAV9 and AAVrh10. For AAV2 and AAVrh10, pool 2 elicited a majority of positive response whereas for AAV4, AAV8 and AAV9 it is the pool 3 (**Supplementary Table S1**). Surprisingly, 73% of AAV9-positive donors are reactive to this serotype only whereas the AAV9, AAV8 and AAVrh10 VP1 amino acid sequences share more than 80% of homology (**Supplementary Table S3**). For AAV2, 4 out of 6 of the positive donors were responding to Pool 2 or 3 with 2 donors responding to both peptide pools. These 2 peptide pools contain immunodominant peptides that were previously described in HLA-A*0201 and HLA-B*0702-restricted donors (29). Some of these immunodominant peptides are also present in AAV9 and AAVrh10 pool 3 although might not be the immunodominant peptides for these particular capsids. Indeed, for these 2 serotypes, donors sharing positive IFN γ -ELISpot do not necessarily respond to the same peptide pools: a positive donor for both AAV2 and AAV9 might have a positive response to AAV2 pool 2 and AAV9 pool 3 (not shown). This observation has been made for all the studied serotype except AAV5 where the only positive donor is also positive for AAV8, AAV9 and AAVrh10 pool 2. An in-depth analysis using a matrix approach would be useful to identify immunodominant peptides depending on donor's HLA genotype and to develop engineered capsids to lower or prevent the adaptive immune response without altering AAV tropism such as described for neutralizing antibody response (27,30).

Then, we performed an in-depth analysis of the positive response to AAV8 and AAV9 (which are currently preferred for systemic administration and used in patients (NCT02122952; NCT03199469; NCT03368742)). They also appear to be the most prevalent serotypes for a cellular immune response in our healthy donor cohort. Our results show that the pre-existing cellular immune response to AAV8 and AAV9 are mainly mediated by CD8 T cells. Regarding the AAV9, some of the donors are also showing an IFN γ secretion mediated by CD4 T cells. This observation has been also described for AAV2 (13) and AAV1 (12) and reactive cells were identified as CD4⁺ effector memory T cells. Since CD8 and CD4 depletions were performed on total PBMCs to evidence a CD8- or CD4-mediated response, we cannot exclude that IFN γ secretion might also be mediated by other immune cells such as natural killer (NK) cells as described by Kuranda *et al.* (31).

Finally, another major concern in AAV-mediated gene transfer is the fact that IFN γ secretion alone, as measured today, is not sufficient to predict the immune outcome of gene transfer. Actually, the IFN γ secretion is not always associated with a loss of transgene expression (32,33) suggesting that, aside the vector serotype, the dose or the transgene, the anti-AAV immune response after gene transfer might vary depending on the immune patient profile. While we performed the prevalence study using the standard IFN γ ELISpot assay, we also performed an in-depth characterization using a multiparametric IFN γ /IL-2/TNF α Fluorospot assay on a limited cohort of healthy donors (n=6-8). Our results show a diversity in immune response profile among the 6 AAV8-positive donors whereas the 8 donors tested for AAV9 showed the same pattern with cells that are not secreting IL-2. The absence of IL-2 secretion suggests that these cells may not be cytotoxic effector T cells and could be related to a CD8 T cell exhaustion. During chronic viral infections, the loss of IL-2 and subsequently TNF α T cell responses are responsible of a decrease of effector responses (34,35). IFN γ is generally maintained a long time, but can also extinguish in the most severely exhausted subsets (35). Whereas chronicity

of WT AAV natural infection has never been clearly demonstrated in humans, exhaustion marker PD1 has been described after AAV-mediated gene transfer in mice, non-human primates and humans (36–38). T cell exhaustion could explain why IFN γ ELISpot positive responses did not systematically translate into liver transaminase elevation in previous clinical trials (7,9,33) and that not major transaminitis responses were reported to date using AAV9 serotype in the clinics (14,39).

CONCLUSION:

Altogether, our study shows a high cellular prevalence to AAV9 and AAV8 in healthy donors based on IFN γ secretion. Since this cytokine cannot be considered as a specific and exclusive marker for deleterious immune responses as shown in clinical trials, it does not appear relevant to prescreen eligible patients to AAV-derived gene therapies yet in opposition to anti-AAV NAbs or TAbs that can prevent cell transduction (40) or lead to innate immune pathway activation (41). Although, the present study highlights the need of better characterizing the pre-existing T cell response to AAV using multiparametric assays and develop relevant *in vitro* and *in vivo* models to test them and foresee the outcome on gene transfer efficacy.

ACKNOWLEDGEMENTS:

The authors acknowledge the Cytocell - Flow Cytometry and FACS core facility (SFR Bonamy, BioCore, Inserm UMS 016, CNRS UAR 3556, Nantes, France) for its technical expertise and help, member of the Scientific Interest Group (GIS) Biogenouest and the Labex IGO program supported by the French National Research Agency (n°ANR-11-LABX-0016-01). We also acknowledge the UMR1089 Vector Core (Vivem) for providing the AAV vectors for ELISA assays screening, the EFS for providing us with buffy coats and Manon Loirat and Marion Grard for their help on performing ELISA and ELISpot assays.

AUTHOR CONTRIBUTIONS:

Conceptualization: R.X, C.V, O.A and G.G; Investigation: R.X, A.A, C.V, N.J, M.D, C.C, J.L.D, A.C, M.G and G.G; Methodology: R.X, A.A, C.V, O.A and G.G; Visualization: R.X, A.A, O.A and G.G; Writing – Original Draft: R.X and G.G; Writing – Review & Editing, R.X, A.A, M.G, O.A and G.G; Supervision, O.A and G.G. Funding acquisition: O.A. and G.G.

AUTHOR DISCLOSURE:

A.A., M.D., N.J., C.C., J.L.D., A.C., M.G., O.A. and G.G. declare no competing financial interests with regards to this work. R.X. is an employee of Roche, Basel, Switzerland. C.V. is an employee of Charles River Laboratories, Evreux, France.

FUNDING STATEMENT

This work was supported by the INSERM, the French Ministry of Research, the FRM (Fondation pour la Recherche Médicale), the University Hospital of Nantes, the Fondation pour la Thérapie Génique en Pays de Loire, Région Pays de Loire (IMBIO-DC consortium), EU Horizon 2020 (UPGRADE - Unlocking Precision Gene Therapy) - grant agreement N_825825, the French National Research Agency (ANR) (ANR-22-CE18-0043-01) and the IHU-CESTI which is supported by the ANR via the “Investment Into The Future” program ANR-10-IBHU-005.

REFERENCES

1. Au HKE, Isalan M, Mielcarek M. Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings. *Front Med.* 2021;8:809118.
2. Wills CA, Drago D, Pietrusko RG. Clinical holds for cell and gene therapy trials: Risks, impact, and lessons learned. *Mol Ther - Methods Clin Dev.* déc 2023;31:101125.
3. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. *Clin Vaccine Immunol CVI.* sept 2011;18(9):1586-8.
4. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. *J Infect Dis.* 1 févr 2009;199(3):381-90.
5. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. *Hum Gene Ther.* juin 2010;21(6):704-12.
6. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JEJ, et al. CD8 + T-cell responses to adeno-associated virus capsid in humans. *Nat Med.* avr 2007;13(4):419-22.
7. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med.* mars 2006;12(3):342-7.
8. Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. *N Engl J Med.* 9 juill 2020;383(2):151-8.
9. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. *N Engl J Med.* 22 déc 2011;365(25):2357-65.
10. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med.* 02 2017;377(18):1713-22.
11. Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, et al. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors. *Mol Ther - Methods Clin Dev.* 13 sept 2019;14:126-33.
12. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. *J Immunol Baltim Md 1950.* 15 juin 2012;188(12):6418-24.
13. Li H, Lasaro MO, Jia B, Lin SW, Haut LH, High KA, et al. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. *Mol Ther J Am Soc Gene Ther.* nov 2011;19(11):2021-30.

14. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med.* 02 2017;377(18):1713-22.
15. Bradbury AM, Rafi MA, Bagel JH, Brisson BK, Marshall MS, Pesayco Salvador J, et al. AAVrh10 Gene Therapy Ameliorates Central and Peripheral Nervous System Disease in Canine Globoid Cell Leukodystrophy (Krabbe Disease). *Hum Gene Ther.* juill 2018;29(7):785-801.
16. Rosenberg JB, Chen A, De BP, Dyke JP, Ballou DJ, Monette S, et al. Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. *Hum Gene Ther.* juin 2021;32(11-12):563-80.
17. Hocquemiller M, Giersch L, Mei X, Gross AL, Randle AN, Gray-Edwards HL, et al. AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates. *Mol Ther Methods Clin Dev.* 8 déc 2022;27:281-92.
18. Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. *Sci Transl Med.* 31 oct 2018;10(465):eaau6414.
19. Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. *Ophthalmology.* 1 sept 2019;126(9):1273-85.
20. Al-Zaidy SA, Kolb SJ, Lowes L, Alfano LN, Shell R, Church KR, et al. AVXS-101 (Onasemnogene Apeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. *J Neuromuscul Dis.* 1 janv 2019;6(3):307-17.
21. Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. *N Engl J Med.* 17 mars 2022;386(11):1013-25.
22. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. *N Engl J Med.* 23 févr 2023;388(8):706-18.
23. Tai CH, Lee NC, Chien YH, Byrne BJ, Muramatsu SI, Tseng SH, et al. Long-term efficacy and safety of eladocogene exuparvovec in patients with AADC deficiency. *Mol Ther.* févr 2022;30(2):509-18.
24. Mendell J, Shieh P, Sahenk Z, Lehman K, Lowes L, Reash N, et al. A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD) (S48.004). *Neurology.* 25 avr 2023;100(17_supplement_2):3035.
25. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. *Gene Ther.* sept 1999;6(9):1574-83.

26. Thwaite R, Pagès G, Chillón M, Bosch A. AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. *Gene Ther.* févr 2015;22(2):196-201.
27. Logan GJ, Mietzsch M, Khandekar N, D'Silva A, Anderson D, Mandwie M, et al. Structural and functional characterization of capsid binding by anti-AAV9 monoclonal antibodies from infants after SMA gene therapy. *Mol Ther.* 5 juill 2023;31(7):1979-93.
28. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, et al. Clades of Adeno-associated viruses are widely disseminated in human tissues. *J Virol.* juin 2004;78(12):6381-8.
29. Hui DJ, Edmonson SC, Podsakoff GM, Pien GC, Ivanciu L, Camire RM, et al. AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes. *Mol Ther — Methods Clin Dev.* 30 sept 2015;2:15029.
30. Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. *Proc Natl Acad Sci U S A.* 13 juin 2017;114(24):E4812-21.
31. Kuranda K, Jean-Alphonse P, Leborgne C, Hardet R, Collaud F, Marmier S, et al. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. *J Clin Invest.* 03 2018;128(12):5267-79.
32. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. *Blood.* 4 juill 2013;122(1):23-36.
33. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. *J Clin Invest.* déc 2013;123(12):5310-8.
34. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. *Nat Med.* mai 2003;9(5):540-7.
35. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. *Immunity.* oct 2007;27(4):670-84.
36. Mays LE, Wang L, Lin J, Bell P, Crawford A, Wherry EJ, et al. AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHC I upregulation on target cells. *Mol Ther J Am Soc Gene Ther.* janv 2014;22(1):28-41.
37. Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP, Calcedo R, et al. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. *Mol Ther J Am Soc Gene Ther.* 7 juin 2017;25(6):1387-94.
38. Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans. *Mol Ther.* 4 mars 2020;28(3):747-57.

39. Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STRIVE): an open-label, single-arm, multicentre, phase 3 trial. *Lancet Neurol.* avr 2021;20(4):284-93.
40. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. *Blood.* 1 mars 2006;107(5):1810-7.
41. West C, Federspiel JD, Rogers K, Khatri A, Rao-Dayton S, Ocana MF, et al. Complement Activation by Adeno-Associated Virus-Neutralizing Antibody Complexes. *Hum Gene Ther.* 1 juin 2023;34(11-12):554-66.

FIGURES AND FIGURE LEGENDS




Figure 1. Cellular immune response prevalence to AAV2, 4, 5, 8, 9 and rh10 in healthy population. PBMCs were restimulated *in vitro* with an overlapping peptide library spanning the VP1 sequence of each serotypes tested (*i.e.* AAV2, 4, 5, 8, 9 and rh10) and analyzed using an IFN γ -ELISpot assay. **A**) Percentage of donors showing an IFN γ -positive response to AAV2 (n=121), AAV4 (n=80), AAV5 (n=84), AAV8 (n=145), AAV9 (n=145), AAVrh10 (n=45). **B**) Coprevalence of the anti-AAV cellular response represented by the percentage of donors showing an IFN γ -positive response to 1, 2, 3 or more than 4 (4+) AAV serotypes. The analysis was performed on 73 healthy donors for AAV2, 4, 5, 8 and 9 and on 40 donors for AAVrh10.




Figure 2. Humoral immune response prevalence to AAV2, 8, 9 and rh10 in healthy population. Sera were collected from healthy human donors and analyzed by ELISA for anti-AAV IgGs. **A)** Percentage of donors showing an anti-AAV IgG response to AAV2 (n=96), AAV8 (n=109), AAV9 (n=92), AAVrh10 (n=39). **B)** Correlation between the anti-AAV humoral and cellular responses in healthy population. Histograms represent percentage of donors with an IFN γ -positive (IFN γ +) or -negative (IFN γ -) response within the healthy population showing an anti-AAV IgG-positive (IgG pos) or -negative (IgG neg) response.




Figure 3. IFN γ secretion to AAV8 and AAV9 is mainly mediated by CD8 T cells. **A)** Cell depletion efficiency analyzed by flow cytometry. Cells were gated from the CD3+CD19- population. Percentages of CD4 (CD4+) and CD8 (CD8+) T cells were determined by flow cytometry before (total PBMCs) and after magnetic separation (CD4- and CD8-depleted PBMCs). **(B)** Total and CD4- and CD8-depleted PBMCs were stimulated *in vitro* with overlapping peptides (15 mers overlapping by 10 aas) spanning the AAV8 VP1 sequence (pool 1–3). This donor is representative of the cohort (n=8). **(C)** Total and CD4- and CD8-depleted PBMCs were stimulated *in vitro* with overlapping peptides (15 mers overlapping by 10 aas) spanning the AAV9 VP1 sequence (pool 1–3). This donor is representative of the cohort showing an IFN γ secretion mediated by both CD4 and CD8 T cells (n=4/8). The 4 remaining donors showed an IFN γ secretion mediated by CD8 T cells only. Negative control consisted of unstimulated cells (medium alone), whereas Concanavalin A (ConA) stimulation was used as a positive control for cytokine secretion. Responses were considered positive when the number of spot-forming colonies (SFCs) per 1e6 cells was >50 and at least 3-fold higher than the negative control condition (dotted line); asterisk (*) denotes a positive response. Error is represented as standard deviation (SD).




Figure 4. Polyfunctional assessment of anti-AAV8 and anti-AAV9 cellular immune responses. PBMCs were collected from healthy human donors (Donor#1 to #8) and analyzed by IFN γ /IL-2/TNF α Fluorespot assays. Donors #1 to #6 were previously identified as positive for both anti-AAV8 and anti-AAV9 cellular immune response. Donors #7 and to #8 were identified as positive for anti-AAV9 cellular immune response. **A)** Representative anti-AAV (left) or positive control (right) response using an IFN γ /IL-2/TNF α Fluorespot assay. **B)** Percentage of anti-AAV8 (upper panel, n=6) and anti-AAV9 (lower panel, n=8) cells within the IFN γ -secreting cell population presenting 1 (IFN γ + only), 2 (IFN γ + only and IFN γ +IL-2+ or IFN γ + only and IFN γ +TNF α +) or 4 functions (IFN γ + only, IFN γ +IL-2+, IFN γ +TNF α + and IFN γ +IL-2+TNF α +).

TABLES

	AAV2	AAV4	AAV5	AAV8	AAV9	AAVrh10
AAV2		25%	0%	100%	75%	0%
AAV4	25%		0%	29%	43%	N/A
AAV5	0%	0%		100%	100%	100%
AAV8	31%	15%	8%		54%	38%
AAV9	9%	9%	3%	21%		14%
AAVrh10	0%	N/A	N/A	75%	75%	

Table 1: Coprevalence of cellular immune response to AAV serotypes 2, 4, 5, 8, 9 and rh10.

Anti-AAV positive donors: AAV2: n=4; AAV4: n=7; AAV5, n=1; AAV8: n=13 AAV9: n=33 AAVrh10: n=4.

	AAV2	AAV8	AAV9	AAVrh10
AAV2		85%	77%	77%
AAV8	79%		93%	71%
AAV9	71%	93%		64%
AAVrh10	100%	100%	90%	

Table 2: Coprevalence of humoral immune response to AAV serotypes 2, 4, 5, 8, 9 and rh10.
Anti-AAV IgG positive donors: AAV2: n=13; AAV8: n=14 AAV9: n=14 AAVrh10: n=10